REG - Allergy Therapeutics - Progression of patient cohorts in PROTECT Trial

Allergy TherapeuticsAnnouncement

10/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240610:nRSJ6958Ra&default-theme=true

RNS Number : 6958R  Allergy Therapeutics PLC  10 June 2024

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Group")

 

Allergy Therapeutics announces progression through patient cohorts in Phase
I/IIa VLP Peanut PROTECT Trial

 

-       First cohort of peanut allergic patients in Phase I/IIa VLP
Peanut PROTECT trial completes subcutaneous dosing with three incremental dose
increases and no relevant safety or tolerability findings

-       Third cohort of healthy subjects completes dosing without
relevant safety or tolerability issues representing a 400-fold dose increase
from the first dose administered

-       Preparations underway for PROTECT trial to progress to last
cohort in healthy subjects and dose escalation to similar high strengths in
peanut allergic patients with biomarker analysis of efficacy included

 

10 June 2024 Allergy Therapeutics (AIM: AGY), the fully integrated commercial
biotechnology company specialising in allergy vaccines, today announces
completion of new cohorts of healthy subjects and peanut allergic patients who
have received increasing dose strengths of its novel virus-like particle
(VLP)-based peanut allergy vaccine candidate ("VLP Peanut").

 

A next-generation peanut allergy immunotherapy

The ongoing Phase I/IIa VLP Peanut PROTECT trial is evaluating the maximum
safe and tolerated dose of the Group's peanut allergy vaccine candidate and
includes assessment of biomarker efficacy in peanut allergic patients.

 

Patients who are allergic to peanuts had previously completed skin-prick
testing in the PROTECT trial and, following the announcement on 12 March 2024
that the first peanut allergic patient had received subcutaneous dosing of the
candidate vaccine, that patient cohort has now completed three incremental
dose levels over 2 months with no safety signals observed.

 

Healthy subjects in the PROTECT trial have now received a 400-fold dose
increase of VLP Peanut, providing strong confidence that the VLP technology
within the vaccine candidate is safe and well tolerated at high cumulative
doses. This is essential for further clinical development of VLP Peanut as the
external safety review committee agreed that the doses administered so far
have been safe and well tolerated and dose increments in next cohorts can
proceed as planned to similarly high doses in peanut allergic patients and to
establish the dose range to be considered for the upcoming Phase IIb study.

 

Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented:
"The promising safety and tolerability data from the latest cohorts in the
PROTECT trial of our peanut allergy vaccine candidate are welcomed, providing
a solid basis for the design of our upcoming Phase IIb study. Ahead of that,
the PROTECT trial continues apace as we look to generate the first
biomarker-led efficacy data, among higher-dose peanut allergic patients in the
next cohorts of the trial."

 

More information about the PROTECT trial can be found on ClinicalTrials.gov
(https://clinicaltrials.gov/ct2/home) under the identifier NCT05476497
(https://clinicaltrials.gov/ct2/show/NCT05476497?term=NCT05476497&draw=2&rank=1)
.

 

 

- ENDS -

 

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon (Nominated Adviser and Broker)

Emma Earl, Freddy Crossley, Mark Rogers, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

 

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. For more information,
please see www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

About the PROTECT trial

The PROTECT trial is being conducted in both healthy subjects and peanut
allergic patients and consists of Part A and Part B. Part A involves
subcutaneous immunotherapy (SCIT) dosing in healthy subjects (Group A1) and
skin-prick testing in peanut allergic patients (Group A2), the latter of which
was completed in April 2023.

 

Part B of the clinical trial is double-blind, placebo-controlled and has
commenced in patients with peanut allergy at multiple clinical trial sites in
the US. Up to 36 peanut-allergic patients will be enrolled in Part B of the
clinical trial, should the dosing advance to the highest dose as currently
planned.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESDZGGVNNLGDZM